AGGF1 and hepatocellular carcinoma: The concurrent reduction in the expression levels of PDGF, Angiopoietin, and AGGF1 among patients in the observation group indicated that taurolactone could potentially disrupt HCC angiogenesis through multifaceted mechanisms.